CSIMarket
 


Lftd Partners Inc   (LIFD)
Other Ticker:  
 
 

LIFD's Free Cash Flow Growth by Quarter and Year

Lftd Partners Inc 's Free Cash Flow results by quarter and year




LIFD Free Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -0.50 1.27 0.78
III Quarter September 1.11 3.01 2.01 -0.38
II Quarter June -0.69 0.14 1.57 -0.38
I Quarter March 0.33 0.39 0.77 -0.36
FY   0.75 3.04 5.62 -0.34



LIFD Free Cash Flow third quarter 2023 Y/Y Growth Comment
Lftd Partners Inc reported drop in Free Cash Flow in the third quarter 2023 by -63.22% to $ 1.11 millions, from the same quarter in 2022.
The fall in the third quarter 2023 Lftd Partners Inc 's Free Cash Flow compares unfavorably to the Company's average Free Cash Flow decline of -29.68%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 41 other companies have achieved higher Free Cash Flow growth. While Lftd Partners Inc ' s Free Cash Flow meltdown of -63.22% ranks overall at the positon no. 2023 in the third quarter 2023.




LIFD Free Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - 62.82 % -
III Quarter September -63.22 % 49.75 % - -
II Quarter June - -91.08 % - -
I Quarter March -15.38 % -49.35 % - -
FY   - -45.91 % - -

Financial Statements
Lftd Partners Inc 's third quarter 2023 Free Cash Flow $ 1.11 millions LIFD's Income Statement
Lftd Partners Inc 's third quarter 2022 Free Cash Flow $ 3.01 millions Quarterly LIFD's Income Statement
New: More LIFD's historic Free Cash Flow Growth >>


LIFD Free Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - -36.82 % -
III Quarter September - 2050 % 28.03 % -
II Quarter June - -64.1 % 103.9 % -
I Quarter March - -69.29 % -1.28 % -
FY (Year on Year)   - -45.91 % - -




Free Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #42
Healthcare Sector #158
Overall #2023

Free Cash Flow Y/Y Growth Statistics
High Average Low
62.43 % -29.68 % -100 %
(Dec 31 2021)   (Dec 31 2017)
Free Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #42
Healthcare Sector #158
Overall #2023
Free Cash Flow Y/Y Growth Statistics
High Average Low
62.43 % -29.68 % -100 %
(Dec 31 2021)   (Dec 31 2017)

Free Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Lftd Partners Inc 's Q/Q Free Cash Flow Growth


Free Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LIFD's III. Quarter Q/Q Free Cash Flow Comment
III. Quarter 2023Periodic Lftd Partners Inc in the influence free cash outflow of $ 1.11 millionsPeriodic influence seem to have added to Lftd Partners Inc 's rebound to positive trends, as LIFD deliverFree Cash Flow of $ 1.11 millions in the III. Quarter 2023 emanate free cash outflow-0.69 millions in the second quarter. Lftd Partners Inc announced in the III. Quarter 2023 Free Cash Flow of $ 1.11 millions compare to free cash outflow recorded in previos quarter.

Within Major Pharmaceutical Preparations industry Lftd Partners Inc achieved highest sequential Free Cash Flow growth. While Lftd Partners Inc 's Free Cash Flow growth quarter on quarter, overall rank is .


Free Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Free Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Free Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LIFD's III. Quarter Q/Q Free Cash Flow Comment
III. Quarter 2023Seasonal Lftd Partners Inc in the influence free cash outflow of $ 1.11 millionsSeasonal influence seem to have led to Lftd Partners Inc 's rebound to positive trends, as LIFD deliverFree Cash Flow of $ 1.11 millions in the III. Quarter 2023 emerging from free cash outflow-0.69 millions in the second quarter. Lftd Partners Inc announced in the III. Quarter 2023 Free Cash Flow of $ 1.11 millions compare to free cash outflow recorded in previos quarter.

Within Major Pharmaceutical Preparations industry Lftd Partners Inc achieved highest sequential Free Cash Flow growth. While Lftd Partners Inc 's Free Cash Flow growth quarter on quarter, overall rank is .


Lftd Partners Inc 's 12 Months Free Cash Flow Growth Year on Year


Free Cash Flow TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Free Cash Flow 12 Months Ending $ 1.25 $ 3.67 $ 4.20 $ 3.95 $ 5.55
Y / Y Free Cash Flow Growth (TTM) -77.44 % -9.08 % -23.85 % -34.01 % 1.66 %
Year on Year Free Cash Flow Growth Overall Ranking # 1230 # 680 # 111 # 66 # 1034
Seqeuential Free Cash Flow Change (TTM) -65.91 % -12.67 % 6.31 % -28.7 % 37.35 %
Seq. Free Cash Flow Growth (TTM) Overall Ranking # 732 # 1667 # 1454 # 853 # 314




Cumulative Free Cash Flow growth Comment
Lftd Partners Inc 's cumulative 12 months Free Cash Flow continue to drop, but on the faster rate at -77.44% year on year, at Sep 30 2023 compare to the -9.08% decrease at Jun 30 2023. If the Lftd Partners Inc 's fiscal year would end at Sep 30 2023, annual Free Cash Flow would be $1 millions.

In the Healthcare sector 92 other companies have achieved higher trailing twelve month Free Cash Flow growth. While Free Cash Flow growth total ranking has deteriorated compare to previous quarter from 680 to 1230.

Free Cash Flow TTM Q/Q Growth Statistics
High Average Low
454.78 %
49.46 %
-77.44 %
 

Free Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 13
Healthcare Sector # 93
Overall # 1230

Free Cash Flow TTM Y/Y Growth Statistics
High Average Low
454.78 %
49.46 %
-77.44 %
 


Free Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 51
S&P 500 # 732
Cumulative Free Cash Flow growth Comment
Lftd Partners Inc 's cumulative 12 months Free Cash Flow continue to drop, but on the faster rate at -77.44% year on year, at Sep 30 2023 compare to the -9.08% decrease at Jun 30 2023. If the Lftd Partners Inc 's fiscal year would end at Sep 30 2023, annual Free Cash Flow would be $1 millions.

In the Healthcare sector 92 other companies have achieved higher trailing twelve month Free Cash Flow growth. While Free Cash Flow growth total ranking has deteriorated compare to previous quarter from 680 to 1230.

Free Cash Flow TTM Q/Q Growth Statistics
High Average Low
454.78 %
49.46 %
-77.44 %
 


Free Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 13
Healthcare Sector # 93
Overall # 1230

Free Cash Flow TTM Y/Y Growth Statistics
High Average Low
454.78 %
49.46 %
-77.44 %
 


Free Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 51
S&P 500 # 732




Other Free Cash Flow Growth
Major Pharmaceutical Preparations Industry Free Cash Flow Growth Trends and Statistics
Healthcare Sector Free Cash Flow Growth Statistics
Free Cash Flow Growth Trends for overall market
LIFD's Free Cash Flow Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Free Cash Flow Growth
Lowest Ranking Free Cash Flow Growth
Free Cash Flow Growth for LIFD's Competitors
Free Cash Flow Growth for Lftd Partners Inc 's Suppliers
Free Cash Flow Growth for LIFD's Customers

You may also want to know
LIFD's Annual Growth Rates LIFD's Profitability Ratios LIFD's Asset Turnover Ratio LIFD's Dividend Growth
LIFD's Roe LIFD's Valuation Ratios LIFD's Financial Strength Ratios LIFD's Dividend Payout Ratio
LIFD's Roa LIFD's Inventory Turnover Ratio LIFD's Growth Rates LIFD's Dividend Comparisons



Companies with similar Free Cash Flow drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Free Cash Flow for the quarter ending Sep 30 2023
Abbvie inc -0.37%$ -0.368 millions
Insulet Corporation-1.23%$ -1.235 millions
National Research Corporation-2.32%$ -2.318 millions
Fonar Corporation-2.93%$ -2.929 millions
Viatris Inc -4.02%$ -4.016 millions
Pediatrix Medical Group Inc -4.07%$ -4.071 millions
Repligen Corp-5.16%$ -5.164 millions
Davita Inc -6.95%$ -6.948 millions
Amgen Inc -7.32%$ -7.320 millions
Adapthealth Corp -7.65%$ -7.653 millions
Dexcom Inc -8.19%$ -8.186 millions
Biogen Inc -10.38%$ -10.378 millions
Avantor Inc -10.69%$ -10.685 millions
Amneal Pharmaceuticals Inc -13.02%$ -13.020 millions
Biomarin Pharmaceutical Inc-14.32%$ -14.322 millions
Organon and Co -17.67%$ -17.666 millions
Hca Healthcare Inc -17.91%$ -17.914 millions
Zimmer Biomet Holdings Inc -25.11%$ -25.111 millions
International Stem Cell Corporation-26.19%$ -26.190 millions
Jazz Pharmaceuticals Plc-26.51%$ -26.507 millions
Universal Health Services Inc -26.74%$ -26.740 millions
Brookdale Senior Living Inc -27.96%$ -27.956 millions
Pacific Health Care Organization Inc -29.00%$ -29.004 millions
Option Care Health Inc -29.95%$ -29.952 millions
Iqvia Holdings Inc -32.44%$ -32.445 millions
Abbott Laboratories-32.48%$ -32.482 millions
Bruker Corporation-36.55%$ -36.547 millions
Sotera Health Company-38.26%$ -38.257 millions
Puma Biotechnology Inc -38.50%$ -38.496 millions
Luna Innovations Inc-38.51%$ -38.514 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com